无缺血器官技术移植研究进展

李冶夫; 张明熙; 吴少海; 陈宏珲; 黄金波; 鲁昌涛; 姚尧; 赵强; 何晓顺

doi:10.3981/j.issn.1000-7857.2023.12.01824

科技导报 >

2024 , Vol. 42 >Issue 8: 76 - 82

DOI: https://doi.org/10.3981/j.issn.1000-7857.2023.12.01824

专题：关键技术与创新驱动

无缺血器官技术移植研究进展

李冶夫 ,
张明熙 ,
吴少海 ,
陈宏珲 ,
黄金波 ,
鲁昌涛 ,
姚尧 ,
赵强 ,
何晓顺

展开

1. 奇点医疗科技(广州)有限公司, 广州 511338;
2. 中山大学附属第一医院, 广州 510062;
3. 广东省医疗器械质量监督检验所, 广州 510663

李冶夫,博士研究生,研究方向为无缺血器官移植,电子信箱:Yefu.li@outlook.com

收稿日期: 2023-12-03

修回日期: 2024-03-15

网络出版日期: 2024-05-22

基金资助

广东省药品监督管理局科技创新项目（S2022ZDZ012）

收起

Research progress of ischemia-free organ transplantation

LI Yefu ,
ZHANG Mingxi ,
WU Shaohai ,
CHEN Honghui ,
HUANG Jinbo ,
LU Changtao ,
YAO Yao ,
ZHAO Qiang ,
HE Xiaoshun

Expand

1. Singularity Medical Technology (Guangzhou) Co., LTD., Guangzhou 511338, China;
2. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510062, China;
3. Guangdong Institute for Quality Supervision and Inspection of Medical Devices, Guangzhou 510663, China

Received date: 2023-12-03

Revised date: 2024-03-15

Online published: 2024-05-22

Fold

摘要

近年来，加入移植等待名单的患者数量逐年升高，但由于供体缺乏，因此扩展标准供体（ECD）器官的利用率逐年增高。从改善病人预后、改变肝内代谢，同时避免缺血-再灌注损伤（IRI），实现肝脏活性评估并提高移植物利用率3个方面，总结了无缺血器官移植（IFOT）技术进展，展望了无缺血器官移植的发展前景。无缺血器官移植技术在未来可能会改变器官移植的方式，技术创新和可移动机器灌注设备开发使用将助推该技术的进一步发展。

关键词： 无缺血器官移植; 常温机械灌注; 缺血-再灌注损伤; 早期同种异体移植物功能障碍

本文引用格式

李冶夫 , 张明熙 , 吴少海 , 陈宏珲 , 黄金波 , 鲁昌涛 , 姚尧 , 赵强 , 何晓顺 . 无缺血器官技术移植研究进展[J]. 科技导报, 2024 , 42(8) : 76 -82 . DOI: 10.3981/j.issn.1000-7857.2023.12.01824

Abstract

Ischemia-reperfusion injury (IRI) is a congenital defect of organ transplantation. Extended criteria donor (ECD) organs are more susceptible to IRI, resulting in a serious contradiction between supply and demand. Although the breakthrough of machine perfusion technology has brought the hope of alleviating IRI, it still cannot eradicate the organ damage caused by IRI. Ischemia-free organ transplantation can completely avoid IRI, improve graft function, improve the prognosis of patients, and expand the source of graft. This article summarizes the latest progress of ischemia-free organ transplantation, and looks forward to the future development of ischemia-free organ transplantation, so as to help researchers and clinicians in related fields understand the latest research status of ischemia-free organ transplantation and provide reference.

Key words： ischemia-free organ transplantation（IFOT）; normothermic machine perfusion（NMP）; ischemia reperfusion injury; early allograft dysfunction

参考文献

[1] Schlegel A, Mergental H, Fondevila C, et al. Machine perfusion of the liver and bioengineering[J]. Journal of Hepatology, 2023, 78(6):1181-1198.
[2] Vodkin I, Kuo A. Extended criteria donors in liver transplantation[J]. Clinics in Liver Disease, 2017, 21(2):289-301.
[3] Manyalich M, Nelson H, Delmonico F L. The need and opportunity for donation after circulatory death worldwide[J]. Current Opinion in Organ Transplantation, 2018, 23(1):136-141.
[4] Da Silva R X S, Weber A, Dutkowski P, et al. Machine perfusion in liver transplantation[J]. Hepatology, 2022, 76(5):1531-1549.
[5] van Rijn R, Schurink I J, de Vries Y, et al. Hypothermic machine perfusion in liver transplantation-a randomized trial[J]. New England Journal of Medicine, 2021, 384(15):1391-1401.
[6] Kron P, Schlegel A, Mancina L, et al. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans[J]. Journal of Hepatology, 2018, 68(1):82-91.
[7] Dengu F, Abbas S H, Ebeling G, et al. Normothermic machine perfusion (NMP) of the liver as a platform for therapeutic interventions during ex-vivo liver preservation:A review[J]. Journal of Clinical Medicine, 2020, 9(4):1046.
[8] van Leeuwen O B, Ubbink R, de Meijer V E, et al. The first case of ischemia-free organ transplantation in humans:A proof of concept[J]. American Journal of Transplantation, 2018, 18(8):2091.
[9] Ceresa C D L, Nasralla D, Pollok J M, et al. Machine perfusion of the liver:Applications in transplantation and beyond[J]. Nature Reviews Gastroenterology&Hepatology, 2022, 19(3):199-209.
[10] Zhao H L, Alam A, Soo A P, et al. Ischemia-reperfusion injury reduces long term renal graft survival:Mechanism and beyond[J]. EBioMedicine, 2018, 28:31-42.
[11] Kalisvaart M, Croome K P, Hernandez-Alejandro R, et al. Donor warm ischemia time in DCD liver transplantation:Working group report from the ILTS DCD, liver preservation, and machine perfusion consensus conference[J]. Transplantation, 2021, 105(6):1156-1164.
[12] Wang L H, Li J, He S, et al. Resolving the graft ischemia-reperfusion injury during liver transplantation at the single cell resolution[J]. Cell Death&Disease, 2021, 12(6):589.
[13] Eden J, von Felten S, Dutkowski P, et al. Reply to:"a multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation"[J]. Journal of Hepatology, 2023, 79(3):116-118.
[14] Schlegel A, Muller X, Mueller M, et al. Hypothermic oxygenated perfusion protects from mitochondrial injury before liver transplantation[J]. EBioMedicine, 2020, 60:103014.
[15] Schlegel A, Muller X, Kalisvaart M, et al. Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation[J]. Journal of Hepatology, 2019, 70(1):50-57.
[16] Jassem W, Xystrakis E, Ghnewa Y G, et al. Normothermic machine perfusion (NMP) inhibits proinflammatory responses in the liver and promotes regeneration[J]. Hepatology, 2019, 70(2):682-695.
[17] Ravikumar R, Jassem W, Mergental H, et al. Liver transplantation after ex vivo normothermic machine preservation:A phase 1(first-in-man) clinical trial[J]. American Journal of Transplantation, 2016, 16(6):1779-1787.
[18] Nasralla D, Coussios C C, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation[J]. Nature, 2018, 557(7703):50-56.
[19] Ghinolfi D, Pezzati D, Rreka E, et al. Transient cold storage prior to normothermic liver perfusion may facilitate adoption of a novel technology[J]. Liver Transplantation:Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2020, 26(1):164-165.
[20] Zhang Y X, Huang C J, Ju W Q, et al. Avoiding ischemia reperfusion injury in liver transplantation[J]. Journal of Visualized Experiments, 2020(166):e61485.
[21] Olthoff K M, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors[J]. Liver Transplantation, 2010, 16(8):943-949.
[22] Huang C J, Huang S Z, Tang Y H, et al. Prospective, single-centre, randomised controlled trial to evaluate the efficacy and safety of ischaemia-free liver transplantation (IFLT) in the treatment of end-stage liver disease[J]. BMJ Open, 2020, 10(5):e035374.
[23] Guo Z Y, Zhao Q, Huang S Z, et al. Ischaemia-free liver transplantation in humans:A first-in-human trial[J]. The Lancet Regional Health Western Pacific, 2021, 16:100260.
[24] Guo Z Y, Zhao Q, Jia Z H, et al. A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease[J]. Journal of Hepatology, 2023, 79(2):394-402.
[25] He X S, Chen G D, Zhu Z B, et al. The first case of ischemia-free kidney transplantation in humans[J]. Frontiers in Medicine, 2019, 6:276.
[26] Yin S L, Rong J, Chen Y H, et al. Transplantation of a beating heart:A first in man[J]. The Lancet Regional Health Western Pacific, 2022, 23:100449.
[27] Guo Z Y, Zhan L Q, Gao N X, et al. Metabolomics differences of the donor livers between in situ and ex situ conditions during ischemia-free liver transplantation[J]. Transplantation, 2023, 107(5):139-151.
[28] Guo Z Y, Xu J H, Huang S Z, et al. Abrogation of graft ischemia-reperfusion injury in ischemia-free liver transplantation[J]. Clinical and Translational Medicine, 2022, 12(4):e546.
[29] Toledo-Pereyra L H, Rodriguez F J, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury[J]. Transplantation, 1993, 55(6):1265-1271.
[30] Schlegel A, van Reeven M, Croome K, et al. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation[J]. Journal of hepatology, 2022, 76(2):371-382.
[31] De Carlis R, Schlegel A, Frassoni S, et al. How to preserve liver grafts from circulatory death with long warm ischemia?A retrospective Italian cohort study with normothermic regional perfusion and hypothermic oxygenated perfusion[J]. Transplantation, 2021, 105(11):2385-2396.
[32] Eden J, Sousa Da Silva R X, Cortes-Cerisuelo M, et al. Utilization of livers donated after circulatory death for transplantation:An international comparison[J]. Journal of Hepatology, 2023, 78(5):1007-1016.
[33] Mergental H, Laing R W, Kirkham A J, et al. Transplantation of discarded livers following viability testing with normothermic machine perfusion[J]. Nature Communications, 2020, 11:2939.
[34] Patrono D, De Carlis R, Gambella A, et al. Viability assessment and transplantation of fatty liver grafts using end-ischemic normothermic machine perfusion[J]. Liver Transplantation, 2022, 29(5):508-520.
[35] Zhang Z H, Tang Y H, Zhao Q, et al. Association of perfusion characteristics and posttransplant liver function in ischemia-free liver transplantation[J]. Liver Transplantation, 2020, 26(11):1441-1454.

Options

文章导航

摘要

本文引用格式

Abstract

参考文献

联系我们

访问统计

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献

联系我们

访问统计